Post hoc analysis revisits non-convulsive status epilepticus severity

A post hoc analysis of non-convulsive status epilepticus in patients with severe impairment of consciousness on 25 September 2026 joined the online catalogue of Seizure: European Journal of Epilepsy. The lead author, Alfonso Canabal-Berlanga, is joined by Isabel Magaña, Claudia Alvargonzález, Marta Sánchez, Beatriz Abad, Lorena Vega Zelaya, Jesus Pastor, and Judit Iglesias.

The article's working title — Non-convulsive status epilepticus with severe impairment of consciousness: a post hoc analysis of clinical severity, refractoriness and outcomes — names three endpoints that practicing epileptologists will recognize as the working vocabulary of any NCSE consultation. Severity scores predict mortality. Refractoriness predicts ICU length of stay. Outcomes determine whether aggressive treatment produced net clinical benefit or simply prolonged a dying process.

What does post hoc mean here?

A post hoc analysis examines data after a study has concluded, mining existing cohorts for patterns the original protocol did not target. For NCSE, that matters. The condition is diagnosed on scalp EEG showing persistent epileptiform activity without convulsive motor signs, often in patients whose presenting complaint is reduced consciousness rather than a clear neurologic emergency. Severity scales such as the Status Epilepticus Severity Score (STESS) and refractoriness definitions anchored to first-, second-, and third-line treatment failure both depend on how aggressively clinicians titrate anesthetics and how reliably they capture EEG endpoints.

The authors do not specify in the available metadata whether the cohort drew from ICU continuous EEG, EMU admissions, or general ward consults. That detail will shape the conclusions.

Why refractoriness matters for the reader

Refractoriness in status epilepticus is not a static patient state. It is a clinical decision point. A patient whose seizures persist after a benzodiazepine and one second-line antiepileptic drug crosses into established status epilepticus by the ILAE 2015 framework. Persistence after anesthetic therapy marks refractory status. How post hoc data reclassify those thresholds directly affects how a monitoring unit triages anesthesia, how an ICU consultant escalates, and how an EMU technician annotates overnight EEG.

What the EEG reader should expect

For scalp EEG readers, the implication is sharper than for imaging work. Montage selection, sensitivity settings, and review duration all affect detection of non-convulsive patterns. Periodic discharges, rhythmic delta activity, and electrographic seizures each carry prognostic weight under the ACNS 2021 nomenclature. A post hoc study revisiting outcomes must either re-adjudicate the EEG or accept the original annotations as ground truth. That choice shapes the conclusions.

The diagnosis requires EEG. A clinical exam alone cannot do the job.

What does this change for the neurophysiologist on call?

Probably this: another reminder that NCSE is a clinical-EEG construct, not a radiology finding. The diagnosis requires scalp EEG (or intracranial monitoring when implanted electrodes exist), and severity assessment requires continuous recording rather than a snapshot. Beyond that reassurance, the paper's specific contribution to severity scoring and refractoriness definitions will become clear only once the results section is read in full.

Looking ahead

The publication date of 25 September 2026 puts the article in the pre-pagination window before final issue assignment. Citation practices in NCSE literature have shifted since the 2015 ILAE reclassification; any new severity and refractoriness data will be absorbed into STESS-based prognostic models and into the ACNS 2021 terminology over the next editorial cycle. For now, the article stands as a marker that a Spanish group has revisited the most operationally consequential subset of NCSE patients: those whose impaired consciousness removes behavioral seizure semiology from the diagnostic picture entirely.